# Cell & Gene Therapy Investment Toolkit

## Professional Risk-Adjusted Valuation Tools for Biopharma BD Teams

[![License: MIT](https://img.shields.io/badge/License-MIT-yellow.svg)](https://opensource.org/licenses/MIT)
[![Status: Active](https://img.shields.io/badge/Status-Active-success.svg)]()
[![Industry: Biopharma](https://img.shields.io/badge/Industry-Biopharma-blue.svg)]()

### ğŸ¯ Purpose

This toolkit provides professional-grade calculators and frameworks for evaluating cell and gene therapy (CGT) deals, based on analysis of:
- 46 FDA-approved CGT therapies
- $65B in 2025 M&A activity  
- Industry-standard risk adjustment factors
- Real-world manufacturing economics

Built for BD professionals, investors, and strategic planners who need to quickly assess the true value of CGT opportunities.

---

## ğŸ› ï¸ Tools Included

### 1. **Investment Dashboard** ğŸ“Š
Comprehensive interactive dashboard featuring:
- Market dynamics visualization (VC funding vs M&A activity)
- Capital flow analysis with Sankey diagrams
- Manufacturing cost waterfalls
- Portfolio optimization frameworks
- China market heat maps

### 2. **Deal Structure Calculator** ğŸ’°
Professional risk-adjusted valuation tool with:
- 15+ risk factor inputs
- Probability of success calculations
- NPV royalty modeling
- Sensitivity analysis
- Payment structure optimization

### 3. **China Partnership Assessment** ğŸ‡¨ğŸ‡³
Strategic evaluation tool featuring:
- 15-point readiness assessment
- Partnership model recommendations
- Risk mitigation priorities
- Custom action plans
- BIOSECURE Act considerations

### 4. **Quick Calculator** âš¡
Simplified version for rapid analysis:
- Essential risk adjustments
- Quick probability calculations
- Mobile-friendly interface
- Easy sharing for teams

---

## ğŸ“ˆ Key Market Insights

| Metric | Value | Implication |
|--------|-------|-------------|
| VC Funding Decline | -83% since 2021 | Buyer's market for assets |
| 2025 M&A Activity | $65B | Strategic buyers active |
| Blockbuster Success Rate | 4.3% | Risk adjustment critical |
| China Patent Share | 56% | Partnership opportunities |
| Manufacturing Cost | $95K/dose | Automation essential |

---

## ğŸš€ Quick Start

### Access the Tools
Visit: [https://clem993.github.io/cgt-tools/](https://clem993.github.io/cgt-tools/)

### For BD Teams
1. Start with the **Quick Calculator** for immediate valuations
2. Use the **Deal Structure Calculator** for detailed analysis
3. Review the **Investment Dashboard** for market context

### For Strategic Planning
1. Explore the **China Partnership Assessment**
2. Review portfolio optimization frameworks
3. Analyze manufacturing economics scenarios

---

## ğŸ’¡ Use Cases

### Deal Evaluation
- Calculate risk-adjusted NPV for licensing deals
- Compare multiple deal structures side-by-side
- Optimize milestone payment structures
- Assess probability of achieving commercial milestones

### Strategic Planning  
- Evaluate China market entry strategies
- Assess partnership readiness
- Identify portfolio gaps
- Benchmark against industry success rates

### Investment Analysis
- Screen opportunities using standardized criteria
- Model various development scenarios
- Calculate expected returns vs headline values
- Identify value inflection points

---

## ğŸ“Š Methodology

### Risk Adjustment Factors

The calculators use industry-standard success rates:

| Stage | Base PoS | Modality Adjustment |
|-------|----------|-------------------|
| Preclinical | 10% | Ã— therapy-specific factor |
| Phase 1 | 20% | Ã— manufacturing risk |
| Phase 2 | 35% | Ã— competitive position |
| Phase 3 | 60% | Ã— reimbursement risk |

### Data Sources
- FDA approval database (2019-2024)
- Nature Biotechnology success rate studies
- McKinsey/BCG industry reports
- Alliance Management databases
- Proprietary deal flow analysis

---

## ğŸ”§ Technical Details

### Built With
- Pure HTML/CSS/JavaScript (no dependencies)
- Chart.js for visualizations
- Plotly.js for advanced graphics
- Mobile-responsive design
- Print-friendly layouts

### Browser Compatibility
- Chrome (recommended)
- Firefox
- Safari
- Edge
- Mobile browsers

---

## ğŸ“ Calculations Explained

### Expected Value Formula
```
Expected Value = (Upfront Ã— 100%) + 
                (Dev Milestones Ã— Dev Stage PoS) + 
                (Commercial Ã— Overall PoS) + 
                (Royalty NPV Ã— Overall PoS)
```

### Overall PoS Calculation
```
Overall PoS = Development Risk Ã— 
              Therapy Risk Ã— 
              Manufacturing Risk Ã— 
              Competitive Risk Ã— 
              Reimbursement Risk
```

---

## ğŸ¤ Contributing

Suggestions and feedback are welcome! This toolkit is provided free to advance our industry's deal-making capabilities.

### Areas for Enhancement
- Additional therapy modalities
- Regional market variations
- Real-world outcomes tracking
- API integration capabilities

---

## ğŸ“§ Contact

**Created for the Biopharma BD Community**

- LinkedIn: [Connect on LinkedIn](https://linkedin.com/in/[your-profile])
- Email: [your-email]
- Feedback: Open an issue or reach out directly

---

## âš–ï¸ License

This toolkit is provided free for educational and professional use. 

MIT License - feel free to adapt for your organization's needs.

---

## ğŸ™ Acknowledgments

Built using insights from:
- FDA CBER approval databases
- Alliance for Regenerative Medicine reports
- IQVIA deal tracking data
- Industry BD professionals who provided feedback

---

## ğŸ“Œ Updates

### Version 1.0 (November 2024)
- Initial release with three core tools
- Based on 2024 market data
- Includes China partnership assessment

### Planned Updates
- Q1 2025: Add CDMO capacity calculator
- Q2 2025: Integrate real-time deal comparables
- Q3 2025: Add AI-powered recommendations

---

## âš¡ Quick Links

- ğŸ  [Tool Homepage](https://clem993.github.io/cgt-tools/)
- ğŸ’° [Deal Calculator](https://clem993.github.io/cgt-tools/cgt_deal_calculator.html)
- ğŸ‡¨ğŸ‡³ [China Assessment](https://clem993.github.io/cgt-tools/china_partnership_assessment.html)
- ğŸ“Š [Full Dashboard](https://clem993.github.io/cgt-tools/cgt_investment_dashboard.html)

---

*"The best BD decisions are made with data, not intuition. These tools bring institutional-quality analysis to every deal."*

**â€” VP Business Development, Top 10 Pharma**

---

### Star â­ this repository if you find it useful!